View Schedule

Monday, Nov. 9, 2020

Pre-Conference Program

9 a.m.–3:15 p.m. EST*

*Dates, times and program schedule subject to change

Immunotherapy Resistance and Failure 

Session I: Defining Immune Checkpoint Inhibitor Resistance 

9 a.m. Introduction

Edward Cha, MD, PhD - Genentech

9:05 a.m.

Definitions of Resistance and Gaps in Current Understanding
Ryan J. Sullivan, MD - Massachusetts General Hospital

9:35 a.m.

Mechanisms of Resistance and Possible New Combinations for Overcoming Paolo A. Ascierto, MD - Istituto Nazionale Tumori IRCCS Fondazione Pascale

9:55 a.m.

Immunotherapy Primary and Acquired Resistance
Antoni Ribas, MD, PhD – University of California Los Angeles

10:15 a.m.

Break

Session II: Primary Resistance 

10:30 a.m.

Approaches to Address Primary Resistance
Siwen Hu-Lieskovan MD, PhD - Huntsman Cancer Institute, University of Utah

10:55 a.m.

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance
Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine

11:20 a.m.

Coupled scRNA-seq and Intracellular Protein Activity Reveals Immune Suppressive Role of TREM2 in Cancer
Yonatan Katzenelenbogen, B.Sc - Weizmann Institute of Science

11:35 a.m.

¬MHC-I and -II Expression Levels on Tumor cells and T cell Response to Immunotherapy in B78 Murine Melanoma Model
Amy K. Erbe, PhD - University of Wisconsin

11:50 a.m.

Break

Session III: Secondary/Acquired Resistance
12:20 p.m.

Approaches to Address Acquired Resistance
Kevin J. Harrington, PhD, MD - The Institute of Cancer Research

12:45 p.m.

Overcoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells
Yong Lu, PhD - Wake Forest School of Medicine

1:00 p.m.

Preclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study
Jing Qing, PhD - Amgen Inc.

1:15 p.m.

Break

Session IV: Therapeutic Strategies for Patients with Resistant Disease
1:30 p.m.

Assessment of Circulating Tumor DNA (ctDNA) and Plasma Microsatellite Instability (MSI) during PD-1 Blockade
Pashtoon M. Kasi, MD, MS - University of Iowa

1:45 p.m.

Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with anti-PD-1 Monotherapy
Xue Bai, MD - Peking University Cancer Hospital & MGH

2:00 p.m.

Precision Microbiome Mapping Identifies a Microbiome Signature Predictive of Immune Checkpoint Inhibitor Response Across Multiple Research Study Cohorts
Matthew J. Robinson, PhD - Microbiotica

2:15 p.m.

Regulatory Considerations
Marc Theoret, MD – U.S. Food and Drug Administration, OHOP

2:40 p.m.

Panel Discussion - All Speakers
Moderators:
Jennifer Gansert, MD, PhD - Amgen
Israel Lowy, MD, PhD - Regeneron Pharmaceuticals

3:10 p.m.

Closing Remarks
Israel Lowy, MD, PhD - Regeneron Pharmaceuticals

Tuesday, Nov. 10, 2020 

Pre-Conference Program

Sponsored Symposia: Medscape: A Deep Dive Into Immunotherapy in Advanced Endometrial Cancer

7:30–8:30 a.m. EST

8 a.m.–9 a.m. EST*

*Dates, times and program schedule subject to change.

World Immunotherapy Council's Virtual Young Investigator Session


8 a.m.

 

Introduction
Bernard A. Fox, PhD - Providence Cancer Institute

8:05 a.m.

A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire
Arianna Draghi – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital

8:15 a.m.

Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients
Denise Goh, BBiomedSc (Hons) – Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore

8:25 a.m.

Expert Discussant
Tanja D. de Gruijl, PhD – VU University Amsterdam

8:30 a.m.

Anti-LunX targeting therapy for lung cancer
Xiaohu Zheng – University of Science and Technology of China

8:40 a.m.

Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients
Emilie Picard, PhD – Health Sciences North/Horizon Sante Nord

8:50 a.m.

Expert Discussant 
Bernard A. Fox, PhD – Providence Cancer Institute

8:55 a.m.

Closing  
Bernard A. Fox, PhD – Providence Cancer Institute

9 a.m.–11:45 a.m. EST*

*Dates, times and program schedule subject to change.

Grant Writing Workshop


9 a.m.

 

Welcome Remarks
Claire Vanpouille-Box, PhD – Weill Medical College of Cornell University

9:05 a.m.

Overview of Grant Opportunities and Principles of Grant Writing
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

9:30 a.m.

K Awards and R01 Grants
William Matsui, MD – University of Texas at Austin

9:55 a.m.

How to Write a Specific Aims Page
Thomas Gajewski, MD, PhD – University of Chicago

10:30 a.m.

Panel Discussion 
Moderator:
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center

Panelists:

William Matsui, MD – University of Texas at Austin
Thomas Gajewski, MD, PhD – University of Chicago
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health

10:45 a.m.

Mock Study Section
Moderator:
Zhang-Zhi Hu, MD- National Institute of Health

Panelists:
Scientific Review Officer - Malgorzata Klauzinska, PhD – National Institutes of Health
Chair - Thomas Gajewski, PhD – University of Chicago
Primary Reviewer - Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Secondary Reviewer - William Matsui, MD – University of Texas at Austin
Third Reviewer – Robyn Gartrell, MD – Columbia University/New York Presbyterian
Reader - Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

11:10 a.m.

What Happens After the Study Section?
Malgorzata Klauzinska, PhD – National Institutes of Health

11:30 a.m.

Panel Discussion 
Moderator:
Grey Wilkinson, PhD – Oncolytics Biotech Inc.

Panelists:
William Matsui, MD – University of Texas at Austin
Thomas Gajewski, PhD – University of Chicago
Pawel Kalinski, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health
Zhang-Zhi Hu, MD- National Institute of Health

11:40 a.m.

Closing Remarks
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

9 a.m.–2:55 p.m. EST*

*Dates, times and program schedule subject to change

Workshop on Engineering Immune Cells for Cancer Therapy 

Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs

9 a.m. Introduction

Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m.

Cellular Immunotherapy for Metastatic Cancers
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

9:25 a.m.

Adoptive Therapy Utilizing TILs
John Haanen, MD, PhD – Netherlands Cancer Institute

9:45 a.m.

Endogenous T cell Therapy for Solid Tumors Malignancies
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

10:05 a.m.

Session I Panel Discussion - Session I Speakers

10:20 a.m.

Break

Session II: Novel Approaches to Enhance CAR T cell Therapy

10:35 a.m.

Next-generation CARs for Blood Cancers
Michael Hudecek, MD –University of Wuerzburg

10:55 a.m.

Advancing Immunotherapy Platforms for the Treatment of Solid Tumors
Saul Priceman, PhD – City of Hope

11:15 a.m.

Understanding Resistance to CAR T-cell Therapy to Develop Next-generation Immunotherapies
Marco Ruella, MD – University of Pennsylvania

11:35 a.m.

Session II Panel Discussion - Session II Speakers

11:50 a.m.

Break

Session III: CAR-Based Strategies Beyond T Lymphocytes
12:05 p.m.

CAR NK cells for the Immunotherapy of Cancer 
Katy Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

12:25 p.m.

The Development of CAR Macrophages and Monocytes for Cancer Immunotherapy
Michael Klichinsky, PharmD, PhD – Carisma Therapeutics

12:45 p.m.

Engineering B cells to Produce Therapeutic Antibodies
Justin J. Taylor, PhD – Fred Hutchinson Cancer Research Center

1:05 p.m.

Session III Panel Discussion - Session III Speakers

1:20 p.m.

Break

Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic
1:35 p.m.

The Evolving Process of Clinical CAR T Cell Manufacturing in the Academic Setting
Isabelle C. Rivière, PhD – Memorial Sloan Kettering Cancer Center

1:55 p.m.

Allogeneic CAR T therapy for Cancer
Barbra J. Sasu, PhD – Allogene Therapeutics

2:15 p.m.

Corona Madness: Flattening the Curve with CAR T 
Carl H. June, MD – University of Pennsylvania

2:35 p.m.

Session IV Panel Discussion - Session IV Speakers

2:50 p.m.

Closing Remarks
Christine Brown, PhD – City of Hope

9 a.m.–3:55 p.m. EST*

*Dates, times and program schedule subject to change.

Primer on Tumor Immunology and Cancer Immunotherapy


Session I: Generating Anti-Tumor Immunity

9 a.m.

 

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

9:05 a.m.

The Adaptive Immune Response
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

9:35 a.m.

Antigen Presenting Cells
Niroshana Anandasabapathy, MD, PhD - Weill Cornell Medicine

10 a.m.

Myeloid-derived Suppressor Cells as Negative Regulators of Immune Responses in Cancer
Dmitry I. Gabrilovich, MD, PhDAstraZeneca

10:25 a.m.

Session I Panel Discussion - Session I Speakers

10:40 a.m.

Break

Session II: Approaches to Immunotherapy I

10:55 a.m.

Introduction
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

11 a.m.

T cell Checkpoint Blockade/Costimulation
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center

11:25 a.m.

Cancer Vaccines
Ugur Sahin, MD – BioNTech Group 

11:50 a.m.

The Suppressive Yin Versus Pro-Inflammatory Yang of the Tumor Myeloid Stroma
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

12:15 p.m.

Session II Panel Discussion - Session II Speakers

12:30 p.m.

Break

Session III: Approaches to Immunotherapy II
12:50 p.m.

Introduction
Yvonne Saenger, MD – Columbia University/New York Presbyterian

12:55 p.m.

Be all that you can B: Imprinting an Antitumor T cell Army
Chrystal M. Paulos, PhD – Winship Cancer Institute at Emory University 

1:20 p.m.

Immunometabolism and its Potential to Modify the Tumor Microenvironment
Greg M. Delgoffe, PhD – University of Pittsburgh

1:45 p.m.

Mobilizing the Immune System with Bispecific Antibodies
John R. Desjarlais, PhD – Xencor, Inc.

2:10 p.m.

Session III Panel Discussion - Session III Speakers

2:25 p.m.

Break

Session IV: Clinical Practice of Immunotherapy 
2:40 p.m.

Introduction
Yvonne Saenger, MD – Columbia University/New York Presbyterian

2:45 p.m.

Immune Biomarkers to Guide Clinical Care
Yvonne Saenger, MD – Columbia University/New York Presbyterian

3:10 p.m.

Immune Related Adverse Events
Michael Postow, MD – Memorial Sloan Kettering Cancer Center 

3:35 p.m.

Session IV Panel Discussion - Session IV Speakers

3:50 p.m.

Closing Remarks
Yvonne Saenger, MD – Columbia University/New York Presbyterian

9 a.m.–3:15 p.m. EST*

*Dates, times and program schedule subject to change.

Immunotherapy Resistance and Failure 

9 a.m. Introduction

Edward Cha, MD, PhD - Genentech

Session I: Defining Immune Checkpoint Inhibitor Resistance

9:05 a.m.

Definitions of Resistance and Gaps in Current Understanding
Ryan J. Sullivan, MD - Massachusetts General Hospital

9:35 a.m.

Mechanisms of Resistance and Possible New Combinations for Overcoming Them
Paolo A. Ascierto, MD - Istituto Nazionale Tumori IRCCS Fondazione Pascale

9:55 a.m.

Immunotherapy Primary and Acquired Resistance
Antoni Ribas, MD, PhD - University of California Los Angeles

10:15 a.m.

Break

Session II: Primary Resistance

10:30 a.m.

Approaches to Address Primary Resistance
Siwen Hu-Lieskovan, MD, PhD – Huntsman Cancer Institute, University of Utah

10:55 a.m.

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance
Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine

11:20 a.m.

Coupled scRNA-seq and Intracellular Protein Activity Reveals Immune Suppressive Role of TREM2 in Cancer
Yonatan Katzenelenbogen, B.Sc - Weizmann Institute of Science

11:35 a.m.

¬MHC-I and -II Expression Levels on Tumor cells and T cell Response to Immunotherapy in B78 Murine Melanoma Model
Amy K. Erbe, PhD - University of Wisconsin

11:50 a.m.

Break

Session III: Secondary/Acquired Resistance
12:20 p.m.

Approaches to Address Acquired Resistance
Kevin J. Harrington, PhD, MD - The Institute of Cancer Research

12:45 p.m.

Overcoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells
Yong Lu, PhD - Wake Forest School of Medicine

1:00 p.m.

Preclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study
Jing Qing, PhD - Amgen Inc.

1:15 p.m.

Break

Session IV: Therapeutic Strategies for Patients with Resistant Disease
1:30 p.m.

Assessment of Circulating Tumor DNA (ctDNA) and Plasma Microsatellite Instability (MSI) during PD-1 Blockade
Pashtoon M. Kasi, MD, MS - University of Iowa

1:45 p.m.

Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with anti-PD-1 Monotherapy
Xue Bai, MD - Peking University Cancer Hospital & MGH

2:00 p.m.

Precision Microbiome Mapping Identifies a Microbiome Signature Predictive of Immune Checkpoint Inhibitor Response Across Multiple Research Study Cohorts
Matthew J. Robinson, PhD - Microbiotica

2:15 p.m.

Regulatory Considerations
Marc Theoret, MD - U.S. Food and Drug Administration, OHOP

2:40 p.m.

Panel Discussion

3:10 p.m.

Closing Remarks
Israel Lowy, MD, PhD - Regeneron Pharmaceuticals

Wednesday, Nov. 11, 2020

Annual Meeting

8:30 a.m. – 8 p.m. EST*
*Dates, times and program schedule subject to change. 

Sponsored Symposia: Natera: Deep Dive into the Clinical Utility of Personalized MRD Monitoring

8–8:30 a.m. EST

Anniversary Awards Ceremony 
Chair:
Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction 
Mario Sznol, MD – Yale School of Medicine

 

Public Service Award

 

Patient Advocacy Award

Session 100: Presidential Welcome & Rosenberg Award Announcement
Chair:
Mario Sznol, MD – Yale School of Medicine

9–9:30 a.m. EST

Mario Sznol, MD – Yale School of Medicine

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship: Discovery, Development, and Application of the PD-1/PD-L1; B7-H1 Antagonist Antibodies
Chair:
Mario Sznol, MD – Yale School of Medicine
9:30–11 a.m. EST

9:30 a.m.

The PD-L1/PD-1 Pathway: Discovery and New Insights
Gordon Freeman, PhD – Dana-Farber Cancer Institute

10 a.m.

Why Were We Interested in Immunity Within the Tumor Microenvironment in the 1990s?
Lieping Chen, MD, PhD – Yale School of Medicine

10:30 a.m.

Discovery of New IO Targets and Mechanisms Leveraging CRISPR
Arlene Sharpe, MD, PhD – Harvard Medical School

11–11:15 a.m. EST

Break

Session 102: Combinatorial Therapies
Co-Chairs:
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Silvia Formenti, MD Weill Cornell Medicine
11:15 a.m.–1:10 p.m. EST
Organized in collaboration with the Radiosurgery Society (RSS)

11:15 a.m.

Introduction

11:20 a.m.

Abstract

11:30 a.m.

Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition
Peter Joyce, PhD - Grey Wolf Therapeutics Limited

11:40 a.m.

A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
James Spicer, PhD, FRCP - King's College London

11:50 a.m.

Expert Discussant

12:05 p.m.

Q&A

12:15 p.m.

NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model
Yun Hu, PhD - The University of Texas MD Anderson Cancer Center

12:25 p.m.

REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

12:35 p.m. Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors
John Thompson, MD - University of Washington Seattle Cancer Care
12:45 p.m.

Expert Discussant
Chandan Guha, MB, BS, PhD – Montefiore Medical Center

1 p.m.

Q&A

 

1:10–1:30 p.m. EST

Break

1–2 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 103: Concurrent Rapid Oral Abstract Presentation Session: Basic Research
Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts institute of Technology
1:30–2 p.m. EST

1:30 p.m.

Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway
Jonathan Boiarsky, BA - Icahn School of Medicine at Mount Sinai

1:38 p.m.

Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer
Bryan Iorgulescu, MD - Dana-Farber Cancer Institute

1:46 p.m.

ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma
Natasha D. Sheybani, PhD - University of Virginia

1:54 p.m.

Q&A

Session 104: Concurrent Rapid Oral Abstract Presentation Session: Clinical
Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina
1:30–2 p.m. EST

1:30 p.m.

Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

1:38 p.m.

Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis
Rosanna N. Lazcano Segura, MD - The University of Texas MD Anderson Cancer Center

1:46 p.m.

Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer
Sarmad Sadeghi, MD - Keck School of Medicine of USC

1:54 p.m.

Q&A

Session 105: Integrating Radiation and Immunotherapy: New Products, Challenges, and Opportunities for Industry-Academic Collaborations
Co-Chairs:
Zachary Morris, MD, PhD – University of Wisconsin, Madison
Andrew Sikora, MD, PhD – University of Texas MD Anderson Cancer Center
2–3:30 p.m. EST

2 p.m.

Introduction
Andrew Sikora, MD, PhD University of Texas MD Anderson Cancer Center

2:05 p.m.

The Immuno-Radiobiology of Radiation Therapy
Zachary Morris, MD, PhD – University of Wisconsin, Madison

2:20 p.m.

Optimal Sequencing of Radiation and Immunotherapy
Silvia Formenti, MD – Weill Cornell Medicine

2:35 p.m.

Design of Clinical Trials Integrating Radiation and Immunotherapy
Jonathan D. Schoenfeld, MD, MPhil, MPH Harvard University

2:50 p.m.

NCI SBIR Opportunities
Kory Hallet, PhD – NCI SBIR Development Center

3 p.m.

Best Practices and Future Perspectives for Integrating Radiation and Immunotherapy Panel Discussion
Mansoor Ahmed, PhD – National Cancer Institute
Michael Basseti, MD, PhD – University of Wisconsin, Madison
Connie Sommers, PhD – National Cancer Institute
Sue L. Currie, PhD Nektar Therapeutics

Sandra Demaria, MD Weill Cornell Medicine
Silvia Formenti, MD – Weill Cornell Medicine
Kory Hallet, PhD – NCI SBIR Development Center
Tibor Keler, PhD – Celldex Therapeutics, Inc.
Jonathan D. Schoenfeld, MD, MPhil, MPH Harvard University
Andrew Sharabi, MD, PhD, FACS – Moores Cancer Center
Ralph Weichselbaum, MD University of Chicago
Kristina H. Young, MD, PhD Earle A. Chiles Research Institute
Samir Khleif, MD – Georgetown University Medical Center
Chiayeng Wang, PhD – National Cancer Institute, NIH
Sophia Pfister, PhD – Varian

3:25 p.m.

Closing Remarks

3:30–4:45 p.m. EST

Break

Concurrent Session 106: Developing Cellular Therapies for Solid Cancers
Co-Chairs:
Stephanie L. Goff, MD, FACS – National Cancer Institute
Avery Posey, PhD – University of Pennsylvania School of Medicine
3:45–5:15 p.m. EST

3:45 p.m.

TILS
Michal Besser, PhD – The Sheba Medical Center at Tel Hashomer

4:05 p.m.

TCR Cells
James C. Yang, MD – National Cancer Institute

4:25 p.m.

CAR for Solid Tumors
Avery Posey, PhD – University of Pennsylvania School of Medicine

4:45 p.m.

NKT Cells
Andras A. Heczey, MD – Baylor College of Medicine

5:05 p.m.

Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model
Amanda N. Lisby, MS - Thomas Jefferson University

Concurrent Session 107: Neoadjuvant Immunotherapies
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

3:45–5:15 p.m. EST

3:45 p.m.

Pan-Tumor Pathologic Response Assessment
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

4:05 p.m.

Neoadjuvant Breast Cancer
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Woman's Cancer Institute

4:25 p.m.

Bladder Cancer
Jianjun Gao, MD, PhD – The University of Texas MD Anderson Cancer Center

4:45 p.m.

3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
Reinhard Dummer, MD - University Hospital of Zurich

5 p.m.

Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma
Raquel Deering, PhD – Regeneron Pharmaceuticals, Inc.

Concurrent Session 108: Diet and Microbiome
Co-Chairs:
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy

3:45–5:15 p.m. EST

3:45 p.m.

Introduction into Microbiome & Diet
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai

4 p.m.

Micronutrients with Immunostimulatory Properties
Guido Kroemer, MD, PhD – Institut Gustave Roussy

4:20 p.m.

Linking the gut microbiome to cancer immunotherapy response
Meriem Messaoudene, PhD – CRCHUM, Bertrand Routy Lab

4:40 p.m.

Interventional Nutrition in Melanoma: Melanoma, Pre and Probiotics
Jennifer L. McQuade, MD – The University of Texas MD Anderson Cancer Center

5 p.m.

Identification of microbial-derived HLA-bound peptides in melanoma
Adi Nagler, MSc - Weizmann

Concurrent Session 109: Innate Immunity: The Next Generation of Targets for Anti-Cancer Immunotherapy
Co-Chairs:
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

3:45–5:15 p.m. EST

3:45 p.m.

Harnessing Tumor Associated Macrophages for Anti-Cancer Therapy
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

4:05 p.m.

Gamma-delta T cells
Adrian Hayday, FRS, F MedSci – Gamma Delta Therapeutics

4:25 p.m.

NK Cells
Andreas Lundqvist, PhD – Karolinska Institutet

4:45 p.m.

AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies
Nancy D. Marin, PhD - Washington University, St. Louis

5 p.m.

High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content
Anastasia Prokopi, PhD - Amsterdam, UMC

5–6 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 110: E-Poster Viewing Session

5:15–5:45 p.m. EST

Session 111: The Surgeon's Impact on Tumor Immunotherapy: Recent Achievements and Future Promise
Co-Chairs:
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

Howard L. Kaufman, MD, FACS – Immuneering Corporation
5:30–6:30 p.m. EST

5:30 p.m

Introduction
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

5:35 p.m.

Oncolytic Viruses: The Importance of Surgical Input
Howard L. Kaufman, MD, FACS – Immuneering Corporation

5:45 p.m. Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer
Maria L. Ascierto, PhD – AstraZeneca
5:50 p.m. Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy
Boris Sepesi, MD - The University of Texas MD Anderson Cancer Center
5:55 p.m. Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable
Diwakar Davar, MD – UPMC Hillman Cancer Center
6:00 p.m. Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation
Lauren Milling, BS - Massachusetts Institute of Technology
6:05 p.m. CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors
Roberta Zappasodi, PhD - Memorial Sloan Kettering Cancer Center
6:10 p.m. Expert Discussant
Steven A. Rosenberg, MD, PhD – National Cancer Institute
6:20 p.m. Q&A

6:30–7 p.m. EST

Break

Replay Session with Live Q&A: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts Institute of Technology

Replay Session with Live Q&A: Rapid Oral Abstracts: Clinical

7–8 p.m. EST

Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina

On-Demand Sessions

Food and Drug Administration (FDA) Update
TBD

National Cancer Institute (NCI) Update
Norman E. Sharpless, MD - National Cancer Institute

Cancer Immunotherapy Trials Network (CITN) Update
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

International Neoadjuvant Melanoma Consortium (INMC) Update
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

SITC Policy Committee Update
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

SITC Women in Cancer Immunotherapy Network (WIN) Update
TBD

Thursday, Nov. 12, 2020

Annual Meeting

8:30 a.m. – 8 p.m. EST*
*Dates, times and program schedule subject to change. 

Sponsored Symposia: OncoSec-DNA Plasmid-based IL-2 Delivered Intratumoral Electroporation: Achieving Meaningful Tumor Responses While Avoiding Systemic Toxicities 

7:30–8:30 a.m. EST

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:32 a.m.

Extraordinary Service Awards

8:44 a.m.

Visionary/Leagacy Award

Session 200: Keynote Address
Chair:
Mario Sznol, MD – Yale School of Medicine
9–9:50 a.m. EST

9 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

Turning Immunologically Quiescent Tumors into Immune Responsive Cancers
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:45 a.m.

Q&A
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:50–10:05 a.m. EST

Break

Session 201: Exploring the Tumor Microenvironment
Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Miriam Merad, MD, PhD– Icahn School of Medicine at Mount Sinai
10:05 a.m.–noon EST

10:05 a.m.

Introduction

10:15 a.m.

Inflammatory Microenvironment
Shannon J. Turley, PhD – Genentech

10:40 a.m.

GBM
Johanna A. Joyce, PhD – University of Lausanne & University Hospital of Lausann

11:05 a.m.

Investigating Genetic Control of the Tumor Microenvironment by Spatial Functional Genomics
Brian D. Brown, PhD – Icahn School of Medicine at Mount Sinai

11:30 a.m.

TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy
Jane Meng, PhD - I-Mab Biopharma

11:45 a.m.

Comparison of Two oHSV Vectors for the Treatment of Glioblastoma
Joseph Jackson, PhD - University of Pittsburgh

Session 202: Late-Breaking Abstract Session
Noon–12:30 p.m. EST

TBA

Abstract

TBA

Abstract

12:30–12:50 p.m. EST

Break

12:30–1:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 203: Concurrent Rapid Oral Abstract Presentation Session: Basic Research
Co-Chairs:
Kristin Anderson, PhD – Fred Huchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics
12:50–1:20 p.m. EST

12:50 p.m.

Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional
suppressors
Paolo D.A. Vignali, BS — The University of Pittsburgh School of Medicine

12:58 p.m.

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Alvaro Teijeira - CIMA Pamplona

1:06 p.m.

Regulatory T cell functional identity is sustained by a glucose: lactate axis that is exploited in the tumor microenvironment
McLane Watson, BS - University Of Pittsburgh

1:14 p.m.

Q&A

Session 204: Concurrent Rapid Oral Abstract Presentation Session: Clinical
Co-Chairs:
Robyn Gartrell, MD, MS – Columbia University
Saman Maleki, PhD – Western University
12:50–1:20 p.m. EST

12:50 p.m.

CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody
Michael D. Farwell, MD - University of Pennsylvania

12:58 p.m.

Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases
Yannick S. Rakké, MD, MSc - Erasmus University Medical Center

1:06 p.m.

Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients
Diego de Miguel Perez, PhD, MSc - University of Maryland

1:14 p.m.

Q&A

Session 205: Toxicities of Cancer Immunotherapy 
Co-Chairs:
Caroline Robert, MD, PhD – Institut Gustave Roussy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

1:20–3:05 p.m. EST

1:20 p.m.

Toxicities from ICIs
Caroline Robert, MD, PhD – Institut Gustave Roussy

1:45 p.m.

Factors Associated with Toxicities of CD19 CAR-T cell Immunotherapy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

2:10 p.m.

CAR-T Studies

2:35 p.m.

Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release
Gabrielle Leclercq, MSc - Roche

2:50 p.m.

Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis
Nazli Dizman, MD - Yale New Haven Hospital

3:05–3:20 p.m. EST

Break

Concurrent Session 206: Vaccines and Immunoprevention
Co-Chairs:
Shizuko Sei, MD – National Cancer Institute
Catherine J. Wu, MD– Dana-Farber Cancer Institute
3:20–4:50 p.m. EST

3:20 p.m.

Tumor Immune Surveillance

3:40 p.m.

Personal Cancer Vaccines: on the Path to Effective Cancer Immunity
Catherine J. Wu, MD – Dana-Farber Cancer Institute

4 p.m.

Cancer Vaccines for Lynch Syndrome Carrier
Eduardo Vilar-Sanchez, MD, PhD  The University of Texas MD Anderson Cancer Center

4:20 p.m.

Q&A

4:30 p.m.

Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes
Rana Falahat, PhD - Moffit Cancer Center

4:40 p.m.

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells
Kristen Radford, PhD - Mater Research Institute

Concurrent Session 207: Gene Editing
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Carl H. June, MD– University of Pennsylvania
3:20–4:50 p.m. EST

3:20 p.m.

Panelists
Matthew Porteus, MD, PhD – Stanford University
Vijay Peddareddigari, MD – Tmunity
Zhaohui Ye, PhD, PI Regulatory – FDA, Center for Biologics Evaluation and Research
Chrystal Louis, MD, MPH – CRISPR Therapeutics

Concurrent Session 208: Bispecific Antibodies in Cancer Immunotherapy
Co-Chairs:
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
Mario Sznol, MD– Yale School of Medicine
3:20–4:50 p.m. EST

3:20 p.m.

CD3 Bispecific

3:40 p.m.

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

4 p.m.

PD1-IL2v: A Next Generation, PD-1-targeted IL-2R Agonist for Cancer Immunotherapy
Pablo Umana – Roche Glycart AG

4:20 p.m.

Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor
Michelle H. Nelson, PhD - Aptevo Therapeutics

4:30 p.m.

HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors
Jack Lin, PhD - Harpoon Therapeutics

4:40 p.m.

AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Hossein Borghaei, MS, DO - Fox Chase Cancer Center

Concurrent Session 209: Immunometabolism and ICI Resistance
Co-Chairs:
Susan M. Kaech, PhD – Salk Institute
Maxim N. Artyomov, PhD– Washington University School of Medicine in St. Louis
3:20–4:50 p.m. EST

3:20 p.m.

Metabolic Regulation of Anti-Tumor NK cells
Susan M. Kaech, PhD – Salk Institute

3:45 p.m.

Metabolic Processes that Affect Anti-Tumor Immune Responses
Santosh Vardhana, MD, PhD – Memorial Sloan Kettering Cancer Center

4:10 p.m.

Targeting Metabolism to Enhance Cancer Immunotherapy
Jonathan D. Powell, MD, PhD – Johns Hopkins Medicine

4:35 p.m.

Metabolic reprogramming of antitumor CD8+ T cell immunity
Alison Jaccard, MS - UNIL

Session 210: E-Poster Viewing Session

4:50–5:20 p.m. EST

5:20–7 p.m. EST

Break

5–6 p.m. EST

Virtual Exhibit and Poster Hall Hours

Replay Session with Live Q&A: Rapid Oral Abstracts: Basic Research

7–8 p.m. EST

Co-Chairs:
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics 

Replay Session with Live Q&A: Rapid Oral Abstracts: Clinical

7–8 p.m. EST

Co-Chair:
Saman Maleki, PhD – Western University

Replay Session with Live Q&A: Rapid Oral Abstracts: Late-Breaking Abstracts

7–8 p.m. EST

Co-Chair:
Roberta Zappasodi, PhD – Memorial Sloan Kettering Cancer Center

On-Demand Sessions

Food and Drug Administration (FDA) Update
TBD

National Cancer Institute (NCI) Update
Norman E. Sharpless, MD - National Cancer Institute

Cancer Immunotherapy Trials Network (CITN) Update
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

International Neoadjuvant Melanoma Consortium (INMC) Update
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

SITC Policy Committee Update
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

SITC Women in Cancer Immunotherapy Network (WIN) Update
TBD

Friday, Nov. 13, 2020

Annual Meeting

8:00 a.m.–8 p.m. EST*
*Dates, times and program schedule subject to change. 

Update Session
Chair: Mario Sznol, MD – Yale School of Medicine
8-8:30 a.m.

8 a.m.

SITC Membership Business Meeting

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:32 a.m.

Extraordinary Service to JITC Awards

8:37 a.m.

Collaborator Awards

8:47 a.m.

NCI Collaboration

8:51 a.m.

Closing
Mario Sznol, MD – Yale School of Medicine
Session 300: 35th Anniversary Keynote Address: T cell Therapy of Cancer
Chair:
Mario Sznol, MD – Yale School of Medicine
9–9:50 a.m. EST

9 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

T cell Therapy of Cancer
Helen E. Heslop, MD – Baylor College of Medicine

9:45 a.m.

Q&A
Helen E. Heslop, MD – Baylor College of Medicine

9:50–10:05 a.m. EST

Break

Session 301: Hot Topic Symposium: COVID-19 and Cancer
Co-Chairs:
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai

10:05 a.m.–12:40 p.m. EST

10:05 a.m.

Infection/Immunology 
Florian Krammer, PhD - Icahn School of Medicine at Mount Sinai

10:30 a.m.

Infection in Cancer Patients Specifically

10:55-11:05 a.m.

Break

11:05 a.m.

Repurposing Cancer Immunotherapies for COVID
Paolo Ascierto , MD – Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale

11:15 a.m.

Repurposing Cancer Immunotherapies for COVID
Florian Krammer, PhD - Icahn School of Medicine at Mount Sinai

11:25 a.m.

Big Data and Informatics – Viral Sequencing and Epitope Identification
Benjamin Greenbaum, MD – Memorial Sloan Kettering Cancer Center

11:35 a.m.

Big data and Informatics – Viral Sequencing and Epitope Identification

11:45 a.m.

Q&A

11:55 a.m.

Panel Discussion: Immunotherapy and COVID Outcomes (ICIs) and Cancer Care in Pandemic

12:15 p.m.

Abstract

12:25 p.m.

Abstract

12:35 p.m.

Closing

12:40–1 p.m. EST

Break

12:30–1:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

Session 302: Late-Breaking Abstract Session
1–1:30 p.m. EST

1 p.m.

Abstract

1:15 p.m.

Abstract

Session 303: Presidential Session
Chair:
Mario Sznol, MD – Yale School of Medicine
1:30–2:55 p.m. EST

1:30 p.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

1:35 p.m.

Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b
Defne Bayik, PhD - Cleveland Clinic

1:50 p.m.

Molecular events regulating solid tumor cell responses to natural killer cells
Michal Sheffer, PhD - Dana-Farber Cancer Institute

2:05 p.m.

Expert Discussant

2:15 p.m.

Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody
Emily Hsiue, MD - Oncology

2:30 p.m.

Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection
Nils Rudqvist, PhD - The University of Texas MD Anderson Cancer Center

2:45 p.m.

Expert Discussant
Robert H. Vonderheide, MD, Dphil – University of Pennsylvania Perelman School of Medicine

2:55–3:10 p.m. EST

Break

Concurrent Session 304: Novel immunotherapies in Myeloid Malignancies
Co-Chairs:
Naval Daver, MD – The University of Texas MD Anderson Cancer Center
Marcela V. Maus, MD, PhD– Massachusetts General Hosptial
3:10–4:40 p.m. EST

3:10 p.m.

CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML)
David Sallman, MD  Moffitt Cancer Center

3:30 p.m.

Bispecific Antibodies
Marion Subklewe, MD – University of Munich

3:50 p.m.

CAR T for AML
Elizabeth Budde, MD, PhD – City of Hope

4:10 p.m.

TBD
Marco L. Davila, MD, PhD – Moffitt Cancer Center

Concurrent Session 305: Reverse Translation for Clinical Trials
Co-Chairs:
Matthew Galsky, MD – Tisch Cancer Institute at Mount Sinai Medical Center
Padmanee Sharma, MD, PhD
 – The University of Texas MD Anderson Cancer Center
3:10–4:40 p.m. EST

3:10 p.m.

TBA
Sangeeta Goswami, MD, PhD – MD Anderson Cancer Center

3:30 p.m.

Clinical Trial Design Considerations to Facilitate Reverse Translation
Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai

3:50 p.m.

Identifying Novel Therapeutics Targets to Overcome Immune Checkpoint Blockade Resistance Through Reverse Translation
Sanjeev Mariathasan, PhD – Genentech

4:10 p.m.

Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
Keun-Wook Lee, MD, PhD - Seoul National University College of Medicine

4:25 p.m.

Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
Ezra Cohen, MD - UC San Diego

Concurrent Session 306: Engineering Immunity: Biomolecular and Genetic Approaches to Generating Novel Therapeutic Function
Co-Chairs:
Yvonne Chen, PhD – University of California, Los Angeles
Kole T. Roybal, PhD – University of California, San Francisco
3:10–4:40 p.m. EST

3:10 p.m.

Biomaterials – Basic Biology
Jennifer H. Elisseeff, PhD – Johns Hopkins School of Medicine

3:35 p.m.

Biomaterials – Immunotherapy
Darrell J. Irvine, PhD – MIT

4 p.m.

Gene Editing

4:25 p.m.

Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models
Kurt Jenkins, PhD - Xilio Therapeutics

Concurrent Session 307: B Cells
Co-Chairs:
Tullia Bruno, PhD – UPMC Hillman Cancer Center
Wolf Fridman, MD, PhD – Cordeliers Research Centre
3:10–4:40 p.m. EST

3:10 p.m.

B cells and Tertiary Lymphoid Structures as biomarkers for prognosis and immunotherapy
Wolf H. Fridman, MD, PhD – Cordeliers Research Centre

3:30 p.m.

The Role of B cells and TLS in Immunotherapy Response
Jennifer Wargo, MD – The University of Texas MD Anderson Cancer Center

3:50 p.m.

Targeting tertiary lymphoid structure heterogeneity and B cell function in non-small cell lung cancer patients
Tullia C. Bruno, PhD – UPMC Hillman Cancer Center

4:10 p.m.

Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer
Ayana Ruffin, MS – University of Pittsburgh

4:17 p.m.

B-cell-based vaccination elicit potent immunity against glioblastoma
Catalina Lee-Chang, PhD – Northwestern University

4:24 p.m.

Expert Discussant
Brad Nelson, PhD – Deely Research Centre at BC Cancer Agency

4:30 p.m.

Q&A

Session 308: E-Poster Viewing Session

4:40–5:10 p.m. EST

4:30–5:30 p.m. EST

Virtual Exhibit and Poster Hall Hours

5:10–7 p.m. EST

Break

Replay Session with Live Q&A: Late-Breaking Abstracts

7–8 p.m. EST

On-Demand Sessions

Food and Drug Administration (FDA) Update
TBD

National Cancer Institute (NCI) Update
Norman E. Sharpless, MD - National Cancer Institute

Cancer Immunotherapy Trials Network (CITN) Update
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

International Neoadjuvant Melanoma Consortium (INMC) Update
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

SITC Policy Committee Update
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

SITC Women in Cancer Immunotherapy Network (WIN) Update
TBD

Saturday, Nov. 14, 2020

Annual Meeting

8:30 a.m.–4:30 p.m. EST*
*Dates, times and program schedule subject to change. 

Anniversary Awards Ceremony
Chair: Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m. EST

8:30 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:33 a.m.

Team Science Award

Session 400: 35th Anniversary Session: Mechanistic Understandings and Misunderstandings

Co-Chairs:
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center
John Wherry, PhD – University of Pennsylvania
9–10:30 a.m. EST

TBA

TBA

10:30–10:45 a.m. EST

Break

Session 401: Biomarkers and Big Data
Co-Chairs:
Michael Angelo, MD, PhD – Stanford University
Nir Hacohen, PhD – Broad Institute
10:45 a.m.–12:40 p.m. EST

10:45 a.m.

Introduction
Nir Hacohen, PhD – Broad Institute

10:55 a.m.

Spatial Analysis of Immune Responses in Tumors
Leeat Keren, PhD – Stanford University

11:20 a.m.

Blood-Based Predictors of Tumor Immunity
Jane Grogan, PhD – Genentech

11:45 a.m.

Capturing heterogeneity and the HLA-presented landscape in melanoma
Yardena Samuels, PhD – Weizmann Institute of Science

12:10 p.m.

Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing
Jiamin Chen, PhD - Stanford University Medical School

12:25 p.m.

Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Michal Harel, PhD - Oncohost LTD

12:30–1:30 p.m. EST Virtual Exhibit and Poster Hall Hours

12:40–1 p.m. EST

Break

Session 402: E-Poster Viewing Session

1–1:30 p.m. EST

Session 403: Poster Symposium
Co-Chairs:
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center
1:30–2:45 p.m. EST

1:30 p.m.

Tumor-specific cytolitic CD4 T cells mediate protective immunity against human cancer
Camilla Jandus, MD, PhD - University of Geneva

 1:40 p.m.

An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer
Elizabeth R. Stirling, MS - Wake Forest University

 1:50 p.m.

Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates
Sara Schad, BS - Memorial Sloan Kettering Cancer Center

 2 p.m.

Adoptive T cell therapy targeting somatic p53 mutations
Peter Kim, PhD - NIH

 2:10 p.m.

Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy
Hussein Abbas, MD, PhD - The University of Texas MD Anderson Cancer Center

2:20 p.m.

Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing
Kartik Sehgal, MD - Dana Farber Cancer Institute

2:30 p.m.

Q&A

2:45–3 p.m. EST

Break

Session 404: Next Generation Immunotherapy Combinations: Navigating FDA, Clinical Trial Design, Diagnostics and Novel Biomarkers
Co-Chairs:
Emily Hopewell, PhD – Indiana University
Ke Liu, MD, PhD – Food and Drug Administration (FDA)
Jason Luke, MD – UPMC Hillman Cancer Center
Marc Theoret, MD – Food and Drug Administration (FDA), CDER
3–4:30 p.m. EST

3 p.m.

Welcome

3:05 p.m.

Navigating the Road to Developing and Pursuing Novel Cellular and Non-Cellular Combination Immunotherapy Clinical Trials: FDA Overview
Adnan A. Jaigirdar, MD, FACS - Food and Drug Administration

3:20 p.m.

FDA Perspective on Areas of Research Needed in Advancing Neo-Adjuvant Immunotherapy Toward Clinical Practice
Nicole Drezner

3:35 p.m.

Difficulties and opportunities in developing cellular therapy and cancer therapeutics clinical trials: science and logistics for investigators
Cassien Yee, MD, PhD – The University of Texas MD Anderson Cancer Center

3:50 p.m.

Improving patient selection in cellular therapy studies and neoadjuvant trials
Rhoda Amaria (MDACC)

On-Demand Sessions

Food and Drug Administration (FDA) Update
TBD

National Cancer Institute (NCI) Update
Norman E. Sharpless, MD - National Cancer Institute

Cancer Immunotherapy Trials Network (CITN) Update
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center

International Neoadjuvant Melanoma Consortium (INMC) Update
Elizabeth M. Burton, MBA – MD Anderson Cancer Center

SITC Policy Committee Update
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

SITC Women in Cancer Immunotherapy Network (WIN) Update
TBD

Schedule At-a-Glance

Monday, Nov. 9
Pre-Conference Programs
(Additional Fees Required)

Immunotherapy Resistance and Failure

Workshop on Engineering Immune Cells for Cancer Therapy

Tuesday, Nov. 10
Pre-Conference Programs
(Additional Fees Required)
Primer on Tumor Immunology and Cancer Immunotherapy™
Grant Writing Workshop
Wednesday, Nov. 11
Annual Meeting

35th Anniversary Annual Meeting

Thursday, Nov. 12
Annual Meeting

35th Anniversary Annual Meeting

Friday, Nov. 13
Annual Meeting


35th Anniversary Annual Meeting

Saturday, Nov. 14
Annual Meeting

35th Anniversary Annual Meeting